Anti-fibrotic effects of thrombin inhibition in systemic sclerosis-associated interstitial lung disease: Proof of concept
Inhibition of thrombin in this SSc-ILD patient treated with low-dose dabigatran etexilate downregulated profibrotic proteins in lung fibroblasts, providing further support for the use of thrombin inhibitors as a therapeutic approach for the treatment of patients with SSc-ILD.
Authors
- Ahmed Ismail (ORCID: https://orcid.org/0000-0002-6337-2341)
- Terrill Huggins
- Galina S. Bogatkevich (ORCID: https://orcid.org/0000-0002-1193-1586)
- Ilia Atanelishvili
- Richard M. Silver (ORCID: https://orcid.org/0000-0002-2038-3278)
Institutions
- Medical University of South Carolina (US)
Publication Details
- Journal
- Journal of Scleroderma and Related Disorders
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1177/23971983241311625
- Citations
- 1
- Primary Topic
- Blood Coagulation and Thrombosis Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- National Scleroderma Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases